Marko Maringer

436 total citations
9 papers, 308 citations indexed

About

Marko Maringer is a scholar working on Molecular Biology, Genetics and Oncology. According to data from OpenAlex, Marko Maringer has authored 9 papers receiving a total of 308 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Molecular Biology, 4 papers in Genetics and 2 papers in Oncology. Recurrent topics in Marko Maringer's work include Virus-based gene therapy research (2 papers), Neurological diseases and metabolism (2 papers) and Prion Diseases and Protein Misfolding (2 papers). Marko Maringer is often cited by papers focused on Virus-based gene therapy research (2 papers), Neurological diseases and metabolism (2 papers) and Prion Diseases and Protein Misfolding (2 papers). Marko Maringer collaborates with scholars based in Germany, Sweden and United States. Marko Maringer's co-authors include Ernesto Bockamp, Christian Spangenberg, Bernhard Zabel, Leonid Eshkind, Stuart T. Fraser, Franz Oesch, Mahavir Singh, Wulf Oehlmann, Steffen Schmitt and Peter Schmidtke and has published in prestigious journals such as Blood, PLoS ONE and Cancer Research.

In The Last Decade

Marko Maringer

9 papers receiving 299 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Marko Maringer Germany	8	219	58	40	37	21	9	308
Joshua Holcomb United States	11	296 1.4×	26 0.4×	37 0.9×	17 0.5×	18 0.9×	22	481
Justin D. Walter United States	7	202 0.9×	33 0.6×	115 2.9×	22 0.6×	18 0.9×	13	432
M.‐C. Farges France	9	130 0.6×	32 0.6×	23 0.6×	42 1.1×	17 0.8×	15	325
Kamela O. Alegre United Kingdom	7	339 1.5×	37 0.6×	64 1.6×	22 0.6×	13 0.6×	10	472
Tara Kashav India	9	165 0.8×	46 0.8×	9 0.2×	58 1.6×	19 0.9×	12	348
Hong-Wei Yue China	9	233 1.1×	17 0.3×	27 0.7×	17 0.5×	41 2.0×	15	324
Urraca Tavarez United States	7	321 1.5×	56 1.0×	26 0.7×	63 1.7×	18 0.9×	9	497
Małgorzata Palczewska Poland	11	228 1.0×	16 0.3×	19 0.5×	33 0.9×	8 0.4×	23	357
Saravanan Kolandaivelu United States	15	538 2.5×	103 1.8×	35 0.9×	31 0.8×	10 0.5×	30	609
Alessia Romano Italy	10	183 0.8×	28 0.5×	19 0.5×	19 0.5×	24 1.1×	15	289

Countries citing papers authored by Marko Maringer

Since Specialization

Citations

This map shows the geographic impact of Marko Maringer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marko Maringer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marko Maringer more than expected).

Fields of papers citing papers by Marko Maringer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marko Maringer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marko Maringer. The network helps show where Marko Maringer may publish in the future.

Co-authorship network of co-authors of Marko Maringer

This figure shows the co-authorship network connecting the top 25 collaborators of Marko Maringer. A scholar is included among the top collaborators of Marko Maringer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marko Maringer. Marko Maringer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

Eigenbrod, Sabina, Petra Frick, Uwe Bertsch, et al.. (2017). Substitutions of PrP N-terminal histidine residues modulate scrapie disease pathogenesis and incubation time in transgenic mice. PLoS ONE. 12(12). e0188989–e0188989. 11 indexed citations

Elamin, Ayssar A., Wulf Oehlmann, Yvonne Braun, et al.. (2017). Novel drug targets in cell wall biosynthesis exploited by gene disruption in Pseudomonas aeruginosa. PLoS ONE. 12(10). e0186801–e0186801. 16 indexed citations

Schnell, R., Wulf Oehlmann, Tatyana Sandalova, et al.. (2012). Tetrahydrodipicolinate N-Succinyltransferase and Dihydrodipicolinate Synthase from Pseudomonas aeruginosa: Structure Analysis and Gene Deletion. PLoS ONE. 7(2). e31133–e31133. 21 indexed citations

Alphey, M.S., Lisa Pirrie, Leah S. Torrie, et al.. (2012). Allosteric Competitive Inhibitors of the Glucose-1-phosphate Thymidylyltransferase (RmlA) from Pseudomonas aeruginosa. ACS Chemical Biology. 8(2). 387–396. 40 indexed citations

Bockamp, Ernesto, Andriy Khobta, Marko Maringer, et al.. (2007). Generation and characterization of tTS‐H4: a novel transcriptional repressor that is compatible with the reverse tetracycline‐controlled TET‐ON system. The Journal of Gene Medicine. 9(4). 308–318. 6 indexed citations

Maringer, Marko, et al.. (2006). Unaltered prion protein cleavage in plasminogen-deficient mice. Neuroreport. 17(5). 527–530. 11 indexed citations

Bockamp, Ernesto, Marko Maringer, Rosario Heck, et al.. (2006). Tetracycline-controlled transgenic targeting from the SCL locus directs conditional expression to erythrocytes, megakaryocytes, granulocytes, and c-kit-expressing lineage-negative hematopoietic cells. Blood. 108(5). 1533–1541. 16 indexed citations

Lausch, Ekkehart, Steffen Schmitt, Thorsten Enklaar, et al.. (2005). Premature Senescence Is a Primary Fail-safe Mechanism of ERBB2-Driven Tumorigenesis in Breast Carcinoma Cells. Cancer Research. 65(3). 840–849. 70 indexed citations

Bockamp, Ernesto, Marko Maringer, Christian Spangenberg, et al.. (2002). Of mice and models: improved animal models for biomedical research. Physiological Genomics. 11(3). 115–132. 117 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact